6260nok
-0,3 %
Date:2026-11-06Time:18:00:00Latest report:Q2-2026List:Oslo BorsTicker:ONCIN
Market Cap:384 mnokEnterprise Value:277 mnokNet Sales:19,5 mnokEarnings:-171,2 mnokEmployees:0ISIN:NO0013711713

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:62,60
MA50:86,39
MA200:62,90
Price/MA200:-0,5 %
RSI (14):31,6
Price/MA50:-27,5 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology